ArticleJournal of lipid research2026
Interleukin-6 stimulates platelet 12-lipoxygenase to drive coagulation in inflammatory arthritis.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Rheumatoid arthritis (RA) is associated with significantly higher thrombotic risk, which is not mechanistically understood. In particular, the detailed mechanisms driving coagulation in arthritis have not been explored, despite the significant impact on patient morbidity and mortality. The role of platelet and blood cell enzymatically oxidized phospholipids (eoxPL) in driving thrombosis and their regulation by inflammation was tested using a mouse model antigen-induced arthritis (AIA) and a human RA cohort. AIA induction significantly elevated plasma thrombin-antithrombin (TAT) complexes, soluble P-selectin (sP-selectin) and serum amyloid A, indicating inflammation and elevated coagulation. Concurrently, platelet-derived eoxPL and their IgG autoantibodies were elevated in whole blood and plasma. These indices were all suppressed by genetic deletion of IL-6Ra, while platelet Alox12 deletion prevented TAT, sP-selectin, and eoxPL/autoantibody increases. Leukocyte Alox15 deletion did not impact circulating TATs or eoxPL. This indicates that IL-6 drives coagulation in AIA via upregulation of platelet Alox12. Conversely, synovial tissue demonstrated raised eoxPL exclusively from Alox15. In human RA, immunoreactivity towards platelet-derived eoxPL was elevated in early disease. Thus, while both LOX isoforms differentially contribute to AIA in mice, only Alox12 promotes thrombosis risk, while evidence for increased eoxPL exposure in early human RA was revealed. In summary, the IL-6/Alox12 axis drives platelet activation in AIA, providing a potential mechanistic explanation for recent clinical trial data proposing that anti-iL-6 therapy is associated with reduced coagulation in early RA. The procoagulant lipid membrane is proposed as a therapeutic target for preventing vascular events in autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.